All Stories

  1. Mapping EQ-5D-5L utility scores from the severe asthma questionnaire in the SHARP CRC registry
  2. Multimorbidity phenotypes and associated characteristics in severe asthma: an observational study of European severe asthma registries
  3. COMSA-MEWS: A simple quantitative algorithm for determining response to biologics in severe asthma, tested in a real-world mepolizumab study
  4. Identifying an At‐Risk Asthma Phenotype: Allergy and Recurrent Infections Predict Severe Disease
  5. Mortality in severe asthma: results from the NORDSTAR cohort
  6. Newly diagnosed eosinophilic granulomatosis with polyangiitis in patients on biologics for severe asthma: A multicenter case series
  7. High‐Dimensional Analysis of Type 2 Lymphocyte Dynamics During Mepolizumab or Dupilumab Treatment in Severe Asthma
  8. Targeting of the IL-5 pathway in severe asthma reduces mast cell progenitors
  9. Use of high-dose inhaled corticosteroids and risk of corticosteroid related adverse events in asthma -findings from the NORDSTAR cohort
  10. Patient-centred composite scores as tools for assessment of response to biological therapy for paediatric and adult severe asthma
  11. Radiomultiomics: quantitative CT clusters of severe asthma associated with multiomics
  12. Characteristics of never-, switching, and persisting users of biologics for severe asthma – a SHARP-CRC study
  13. Characteristics of severe asthma patients requiring ICU treatment across the SHARP CRC
  14. Clinical characteristics of severe asthma patients in Europe, according to the percentage of GDP spent on healthcare- a SHARP-CRC study
  15. Dose-dependent association between inhaled corticosteroids and risk of corticosteroid related adverse events in asthma
  16. Health-related quality of life (HRQoL) in depression defined by clinicians and patients in severe asthma. Data from SHARP CRC
  17. Health-related quality of life and asthma control in patients receiving or not receiving biologic treatments for severe asthma. Data from SHARP CRC
  18. High-dose inhaled corticosteroid use associated with increased cardiovascular risk in patients with asthma
  19. Initial data analysis of the SHARP CRC patient population reveals a large heterogeneity among European patients with severe asthma
  20. Multimorbidity burden in severe asthma across the SHARP CRC
  21. Phospholipid composition of the respiratory tract lining fluid (RTLF) in subjects with Asthma and COPD
  22. Recurrent respiratory infections and allergy hallmarks at-risk progression to severe asthma
  23. Relationship between the Severe Asthma Questionnaire and the EQ-5D-5L for health-related quality of life in the SHARP CRC registry
  24. Severe Asthma Multimorbidity Clusters Across Europe; Findings From SHARP
  25. A modified COMSA score is a good tool to identify responders and non-responders to mepolizumab in severe asthma
  26. Late Breaking Abstract - Dynamics of the blood innate lymphoid cell compartment in patients with severe asthma undergoing type 2 biologics treatment: Initial findings in the BIOCROSS study
  27. Severe asthma trajectories in adults: findings from the NORDSTAR cohort
  28. Low levels of endogenous anabolic androgenic steroids in females with severe asthma taking corticosteroids
  29. Prevalence and management of severe asthma in the Nordic countries: findings from the NORDSTAR cohort
  30. Definitions of non-response and response to biological therapy for severe asthma: a systematic review
  31. Development of Core Outcome Measures sets for paediatric and adult Severe Asthma (COMSA)
  32. The prevalence of severe asthma, use of oral corticosteroid and management strategies in the Nordic countries: results from the pan-Nordic NORDSTAR cohort
  33. Suppressive effect of corticosteroid treatment on urinary levels of androgens and cortisol in mild and severe asthma
  34. The effect of the COVID-19 pandemic on severe asthma care in Europe - will care change for good?
  35. The effect of the COVID-19 pandemic on severe asthma care in Europe - will care change for good?
  36. Eosinophilic airway diseases: basic science, clinical manifestations and future challenges
  37. Mepolizumab decreases urinary excretion of LTE4 in severe asthma
  38. NORDSTAR – Paving the way for a new era in asthma research
  39. Severe asthma in different European registries
  40. Characteristics and treatment regimens across ERS SHARP severe asthma registries